Platelet rich plasma (PRP) was obtained by centrifugation at 50g for 15min
from whole blood anticoagulated with one-tenth volume of 3.8% trisodium citrate.
Platelet suspension was prepared as follows. PRP mixed with 15% volume of acid citrate dextrose (ACD) was centrifuged at 1,000g for 10min, and sedimented pellets were washed twice with modified Tyrode buffer (pH 7.4). Platelets were finally re suspended in the same buffer at a concentration indicated. The multimeric structures of plasma and platelet vWF were analyzed by thin layer sodium dodecyl sulphate (SDS) agarose gel electrophoresis according to the method of Ruggeri and Zimmerman.14,15 Plasma from patients or normal individuals was diluted by 20 times with sample buffer (0.01M Tris-HCl, 0.001M EDTA, 2% SDS, 8M urea, pH 7.4) before it was applied to the agarose gel. Samples were also prepared for analysis of platelet vWF. PRP was obtained from whole blood mixed with one tenth volume of a solution containing 3.8% trisodium citrate, 10mM leupeptin, 50mM
EDTA and 60mM N-ethylmalaimide. Platelets were washed twice with modified Tyrode buffer, pH 7.4, containing 0.38% trisodium citrate, 0.1mM leupeptin, 6mM N-ethyl malaimide, and finally resuspended in the same buffer. These platelet suspensions were lysed with 10 times volume of sample buffer for electrophoresis. All samples were run at constant current of 20mA until the samples reached the running gel and then at 10mA until the tracking dye reached the end of the gel. vWF multimers were identified by exposing the dried gels to 125I-labelled affinity-purified antibodies to human vWF (a generous gift of Dr. T. S. Zimmerman) followed by autoradiography. The assay of vWF and VIII: C was performed in all patients and the results were shown in (Fig. 1 ).
Both plasma VIIIR: RCo and VIIIR: Ag were decreased in five patients who had prolonged bleeding time (bleeders). On the other hand, they were normal in six patients who had normal bleeding time (non-bleeders). In bleeders the mean values of plasma VIIIR: RCo and VIIIR: Ag were 42% and 55%, respectively, while 90% and 125%, respectively, in non-bleeders. The mean value of VIII: C was within normal range both in bleeders and non-bleeders, although it was lower in bleeders than in non-bleeders.
In nine patients (three bleeders and six non-bleeders), plasma vWF multimeric structures were analysed by SDS-agarose gel electrophoresis. All of three bleeders In case, multimeric structures of plasma vWF were also analyzed before and after treatment. Lack of vWF larger multimers was observed before treatment, while vWF multimeric structures were normal after treatment (Fig. 3) .
To see the correlations between platelet counts and VIIIR:RCo, these two parame ters were measured simultaneously during the course of illness in all patients and were potted in (Fig. 4a and Fig. 4b ). Figure 4a represented the patients who had pro longed bleeding time, while the data from patients with normal bleeding time were shown in (Fig. 4b ). In patients with prolonged bleeding time, significant inverse corre lations were observed between platelet counts and VIIIR:RCo. On the other hand, no significant correlations were seen in non-bleeders.
DDAVP has been used for treatment of bleeding tendency in vWF, since this agent is able to release vWF from endothelial cells when injected intravenously. To elucidate the mechanism of deficient vWF larger multimers in patients with essential thrombocythemia, DDAVP was administered to the patient (case) who showed the prolonged bleeding time and lack of vWF larger multimers. Before and after infusion, plate!et count, bleeding time, plasma VIIR:Ag, VIIIR:RCo and platelet aggregation were measured simultaneously (Table 3) .
Platelet counts were not significantly changed, but bleeding time became shortened vWF in Essential Thrombocythemia GPIb is known to function as a receptor of vWF, platelet membrane glycoproteins were analyzed by SDS polyacrylamide gel electrophoresis in seven patients with essential thrombocythemia. Labelling pattern and electrophoretic mobility of GPIb in seven pa tients including two bleeders were found to be normal as illustrated in (Fig. 6) . Rinrdina of vWF to natient's n!atelets was also determined in seven patients to see whether GPIb in this patients function properly as vWF receptor. There was no signifi cant difference among normal controls, bleeders, and non-bleeders in vWF binding to platelets (Table 4) . It is well known that addition of ristocetin to a stirred platelet suspension in the presence of vWF causes platelets to agglutinate. This ristocetin induced platelet agglutination (RIPA) was found to be nearly absent in all patients with essential thrombocythemia, irrespective of the value of plasma vWF. This findings were unexpected since RIPA is now considered to represent in vitro approximation of in vivo process such as platelet adhesion to subendothelium. The following experiments were, therefore, carried out to clarify the reason for the defective RIPA. RIPA was measured under the various experimental conditions as described in the method. When normal platelets were resuspended in patient's plasma, RIPA was absent. On the other hand, RIPA was normally demonstrated when patient's platelets were resuspended in normal plasma as shown in (Fig. 7) . This result indicated that the patient's plasma contained some factors to inhibit RIPA, while the patient's platelets were not responsible for the defective RIPA in essential thrombocythemia.
To explore the causative factors in plasma for defective RIPA, the following experiments were performed. It is well known that RIPA is completely inhibited by anti-GPIb monoclonal antibody. When this monoclonal antibody was preincubated with patient's plasma at room temperature for 5min, its inhibitory effect on RIPA was abolished. Plasma from normal individuals had minimal effect on this monoclonal antibody to inhibit RIPA (Fig. 8) . These results indicated the presence of some substances in patient's plasma which could react with anti-GPIb monoclonal antibody. To further define the exact nature of these substances, competitive inhibition assay of glycocalicin, soluble proteolytic fragment of GPIb in plasma was performed. As shown in Table 5 , plasma glycocalicin was found to be significantly increased in five patients with essential thrombocythemia examined. 
